

 Early Warning System

EIB-20240866

SOUTH AFRICA END TO END VACCINE SITE (HDX)



Quick Facts

| | |
|--------------------------------|---|
| Countries | South Africa |
| Financial Institutions | European Investment Bank (EIB) |
| Status | Proposed |
| Bank Risk Rating | U |
| Borrower | THE BIOLOGICALS AND VACCINES INSTITUTE OF SOUTHERN AFRICA (PTY) LTD |
| Sectors | Education and Health, Industry and Trade |
| Investment Type(s) | Loan |
| Investment Amount (USD) | \$ 85.90 million |
| Project Cost (USD) | \$ 202.72 million |



Project Description

According to bank provided information, this project supports the construction, furnishing and validation of a multi-vaccine manufacturing facility by an established Promoter that is a national supplier of vaccines.

The project supports the Promoter to scale up their current fill and finish vaccine manufacturing facility and expand into an end-to-end multi-vaccine manufacturing facility. At completion the facility will include a drug substance suite as well as formulation, fill, finish, quality control and release capabilities for commercial scale vaccine production. Additionally, the project is expected to facilitate technology transfer of vaccines for infectious diseases included in routine immunisation schedules.



Investment Description

- European Investment Bank (EIB)



| Private Actor 1 | Private Actor 1 Role | Private Actor 1 Sector | Relation | Private Actor 2 | Private Actor 2 Role | Private Actor 2 Sector |
|-----------------|----------------------|------------------------|----------|---|----------------------|------------------------|
| - | - | - | - | BIOLOGICALS AND VACCINES INSTITUTE OF SOUTHERN AFRICA (PTY) LTD | Client | Industry and Trade |



Contact Information

Contact information not provided at the time of disclosure

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check:

http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at:

<http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>